Independent register of U.S. FDA drug recalls · updated Oct 12, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

Pyridoxine HCL

Lack of Assurance of Sterility: FDA inspection raised sterility assurance concerns

Terminated Sterility / contamination First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy D-0041-2022
Class II · Moderate risk

Glutathione 200mg/Ml Mdv

Lack of Assurance of Sterility: FDA inspection raised sterility assurance concerns

Terminated Sterility / contamination First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy D-0038-2022
Class II · Moderate risk

Cyclosporine 2% Mct Oil Susp

Lack of Assurance of Sterility: FDA inspection raised sterility assurance concerns

Terminated Sterility / contamination First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy D-0035-2022
Class II · Moderate risk

Ascorbic Acid

Lack of Assurance of Sterility: FDA inspection raised sterility assurance concerns

Terminated Sterility / contamination First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy D-0032-2022
Class II · Moderate risk

Ascorbic Acid

Lack of Assurance of Sterility: FDA inspection raised sterility assurance concerns

Terminated Sterility / contamination First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy D-0031-2022
Class II · Moderate risk

Magnesium Chloride

Lack of Assurance of Sterility: FDA inspection raised sterility assurance concerns

Terminated Sterility / contamination First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy D-0029-2022
Class II · Moderate risk

Calcium Chloride

Lack of Assurance of Sterility: FDA inspection raised sterility assurance concerns

Terminated Sterility / contamination First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy D-0028-2022
Class II · Moderate risk

Micafungin for Injection

Labeling; Incorrect or Missing Package Insert: The package insert provided with the product does not include all required sections approved for this product. This includes aspects of Adverse Reactions, Drug Interactions and Use in Specific Populations.

Terminated Labeling / mix-up Xellia Pharmaceuticals USA, LLC NDC 70594-037-01 D-0757-2021
Class II · Moderate risk

Micafungin for Injection

Labeling; Incorrect or Missing Package Insert: The package insert provided with the product does not include all required sections approved for this product. This includes aspects of Adverse Reactions, Drug Interactions and Use in Specific Populations.

Terminated Labeling / mix-up Xellia Pharmaceuticals USA, LLC NDC 70594-036-01 D-0756-2021
Class II · Moderate risk

Artificial Tears Ointment

Non-Sterility - OOS sterility testing observed during 12-month controlled room temperature stability testing. The microbiological investigation identified the organism as a member of the Bacillus cereus group.

Terminated Microbial contamination Akorn, Inc. NDC 17478-062-35 D-0786-2021

Recalls by year